Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q4 FY2026, quarter ended Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 2/302% above fair value
$8.69−1.98 (-18.56%)
Close on Nov 17, 2026Market cap $253.10MP/E –Yield –
Enanta Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Enanta Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$42.56M. For fiscal 2026 it was -$42.56M. The highest annual figure on record is $76.67M in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Sep 30, 2026 | -$42.56M | – |
| FY2025 | Sep 30, 2025 | -$19.27M | – |
| FY2024 | Sep 30, 2024 | -$78.76M | – |
| FY2023 | Sep 30, 2023 | -$103.15M | – |
| FY2022 | Sep 30, 2022 | -$84.78M | – |
| FY2021 | Sep 30, 2021 | -$70.00M | -1087.5% |
| FY2020 | Sep 30, 2020 | $7.09M | -90.1% |
| FY2019 | Sep 30, 2019 | $71.42M | +144.4% |
| FY2018 | Sep 30, 2018 | $29.22M | -44.5% |
| FY2017 | Sep 30, 2017 | $52.65M | +47.0% |
| FY2016 | Sep 30, 2016 | $35.81M | -53.3% |
| FY2015 | Sep 30, 2015 | $76.67M | +280.0% |
| FY2014 | Sep 30, 2014 | $20.18M | +89.4% |
| FY2013 | Sep 30, 2013 | $10.65M | -52.9% |
| FY2012 | Sep 30, 2012 | $22.62M | -5.8% |
| FY2011 | Sep 30, 2011 | $24.02M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ3 2026 | Sep 30, 2026 | -$13.73M | – |
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$9.97M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$7.16M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$11.70M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$6.49M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$16.80M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$10.40M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$14.78M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$28.60M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$24.99M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$21.60M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$32.13M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$13.78M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$35.64M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$15.53M | – |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -$29.60M | – |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -$26.38M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$13.27M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$21.02M | – |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -$29.51M | – |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -$4.58M | -131.2% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$14.89M | -220.4% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$15.46M | -280.9% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$4.49M | -277.2% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $14.67M | -51.2% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $12.36M | -59.1% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $8.55M | -69.8% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $2.53M | -37.4% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $30.09M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $30.25M | +586.2% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $28.34M | -50.5% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $4.05M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$7.58M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $4.41M | +40.2% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $57.31M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$4.80M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$3.00M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $3.15M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$2.13M | – |
See a number that looks wrong?